Profile Response Detail

Molecular Profile KRAS wild-type
Therapy Cetuximab
Indication/Tumor Type colorectal cancer
Response Type predicted - sensitive
Create By tyin
Update By djd


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
KRAS wild-type colorectal cancer predicted - sensitive Cetuximab Phase III Actionable In a Phase III trial, addition of Erbitux (cetuximab) or Avastin (bevacizumab) to chemotherapy (FOLFIRI or mFOLFOX6) resulted in similar median overall survival (30.0 vs 29.0 months, HR=0.88, p=0.08) and median progression-free survival (10.5 vs 10.6 months, HR=0.95, p=0.45) in KRAS wild-type colorectal cancer patients (PMID: 28632865). 28632865
KRAS wild-type colorectal cancer predicted - sensitive Cetuximab Clinical Study Actionable In a clinical study, KRAS wild-type colorectal cancer patients demonstrated a greater response to Erbitux (cetuximab) treatment compared to KRAS mutant colorectal cancer patients, including an objective response of 41% (27/66) vs 0% (0/42), a median overall survival of 43 weeks vs 27.3 weeks, and an overall survival of 74.9 weeks vs 30.6 weeks, respectively (PMID: 17998284). 17998284
PubMed Id Reference Title Details
(28632865) Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. Full reference...
(17998284) KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Full reference...